Patents by Inventor Brian Alan Lanman

Brian Alan Lanman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200030324
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 31, 2019
    Publication date: January 30, 2020
    Inventors: Shon BOOKER, John Gordon ALLEN, Brian Alan LANMAN, Ryan Paul WURZ, Ning CHEN, Victor J. CEE, Patricia LOPEZ, Aaron C. SIEGMUND, Michael D. BARTBERGER
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10532042
    Abstract: Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 14, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10519146
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 31, 2019
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190381064
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190374542
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 12, 2019
    Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon Booker, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190375749
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: June 10, 2019
    Publication date: December 12, 2019
    Inventors: Jian CHEN, Nuria A. TAMAYO, Longbin LIU, Hui-Ling WANG, Brian Alan LANMAN, Ryan Paul WURZ, Youngsook SHIN, Victor J. CEE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190343838
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 14, 2019
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190345169
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 9, 2019
    Publication date: November 14, 2019
    Inventors: Ana Elena MINATTI, Jonathan Dante LOW, Ryan Paul WURZ, Brian Alan LANMAN, Victor J. CEE, Michael D. BARTBERGER, Margaret CHU-MOYER
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190336514
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 7, 2019
    Inventors: Ryan Paul WURZ, Victor J. CEE, Albert AMEGADZIE, Ning CHEN, Brian Alan LANMAN, Michael D. BARTBERGER
  • INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME
    Publication number: 20190077801
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Inventors: Brian Alan LANMAN, Shon BOOKER, Clifford GOODMAN, Anthony B. REED, Jonathan D. LOW, Hui-Ling WANG, Ning CHEN, Ana Elena MINATTI, Ryan WURZ, Victor J. CEE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20180334454
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 21, 2018
    Publication date: November 22, 2018
    Inventors: Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, David John KOPECKY, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Nobuko NISHIMURA, Youngsook SHIN, Nuria A. TAMAYO, John Gordon ALLEN, Jennifer Rebecca ALLEN
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20180289720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 28, 2018
    Publication date: October 11, 2018
    Applicant: Amgen Inc.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20180177767
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: December 21, 2017
    Publication date: June 28, 2018
    Applicant: AMGEN INC.
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • APELIN POLYPEPTIDES
    Publication number: 20170107255
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Application
    Filed: June 10, 2015
    Publication date: April 20, 2017
    Applicant: AMGEN INC.
    Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • Azole compounds as PIM inhibitors
    Patent number: 9321756
    Abstract: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: April 26, 2016
    Assignee: AMGEN INC.
    Inventors: Hui-Ling Wang, Victor J. Cee, Bradley J. Herberich, Claire L. M. Jackson, Brian Alan Lanman, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker
  • Inhibitors of PI3 kinase and/or mTOR
    Patent number: 8772480
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: July 8, 2014
    Assignee: Amgen Inc.
    Inventors: Kristin L. Andrews, Yunxin Y. Bo, Shon Booker, Victor J. Cee, Noel D'Angelo, Bradley J. Herberich, Fang-Tsao Hong, Claire L. M. Jackson, Brian Alan Lanman, Hongyu Liao, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Liping H. Pettus, Anthony B. Reed, Adrian Leonard Smith, Seifu Tadesse, Nuria A. Tamayo, Bin Wu, Ryan Wurz, Kevin C. Yang
  • Azole Compounds as PIM Inhibitors
    Publication number: 20140187553
    Abstract: The invention relates to bicyclic compounds of formulas I and Ia, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.
    Type: Application
    Filed: March 21, 2012
    Publication date: July 3, 2014
    Applicant: AMGEM INC.
    Inventors: Hui-Ling Wang, Victor J. Cee, Bradley J. Herberich, Claire L.M. Jackson, Brian Alan Lanman, Thomas Nixey, Liping H. Pettus, Anthony B. Reed, Bin Wu, Ryan Wurz, Andrew Tasker
  • S1P Receptor Modulating Compounds and Use Thereof
    Publication number: 20110212940
    Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: EPIX PHARMACEUTICALS, INC.
    Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
  • S1P receptor modulating compounds and use thereof
    Patent number: 7919519
    Abstract: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: April 5, 2011
    Assignee: Epix Pharmaceuticals Inc.
    Inventors: Roland Burli, Victor J. Cee, Jennifer Golden, Brian Alan Lanman, Susana Neira, Ashis Saha, Nili Schutz, Xiang Yu, Dilara McCauley, Mercedes Lobera, Yael Marantz, Jian Lin, Srinivasa R. Cheruku, Pini Orbach, Anurag Sharadendu, Robert C. Penland, Kimberley Gannon, Sharon Shacham, Silvia Noiman, Oren Becker, Zhaoda Zhang
  • S1P1 receptor agonists and use thereof
    Patent number: 7842685
    Abstract: The present invention relates to compounds of Formula (I): that are have activity as S1P receptor modulating agents, more specifically to specifically compounds that are S1P1 receptor agonists. The invention also related to the use of such compounds to treat diseases associated with inappropriate S1P1 receptor activity such as autoimmune diseases.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: November 30, 2010
    Assignee: Amgen Inc.
    Inventors: Victor J. Cee, Michael J. Frohn, Brian Alan Lanman, Susana C. Neira, Anthony B. Reed, Kelvin K. C. Sham